When Can You Do Non-Invasive Prenatal Testing (NIPT)?

Most providers offer NIPT starting at 10 weeks of gestation, and major guidelines recommend it from that point onward for screening of the common trisomies (21, 18, and 13) in singleton pregnancies. The test works by analyzing fragments of placental DNA circulating in your blood, and those fragments need to reach a high enough concentration for the lab to read them reliably. That threshold is the main reason there is a minimum gestational age, and it is also why certain factors like body weight or medications can push the practical window later than you might expect.

Why Ten Weeks Is the Standard Starting Point

The American College of Medical Genetics and Genomics (ACMG) recommends NIPT from 10 weeks of gestation onward as a preferred screening method over traditional first-trimester screening for trisomies 21, 18, and 13 in singleton pregnancies.¹ By 10 weeks, the concentration of placental DNA fragments in your bloodstream, often called the fetal fraction, is generally high enough for labs to produce a reliable result. Most labs require a fetal fraction of at least 4% to issue a report.

What is actually being measured is not exactly “fetal” DNA in the traditional sense. The fragments come from the outer layer of the placenta, specifically the cytotrophoblast cells that are constantly turning over and releasing DNA into your circulation.² Because the placenta and the fetus usually share the same genetic makeup, counting these fragments serves as a proxy for detecting chromosomal abnormalities in the baby. But this distinction matters: in rare cases, the placenta and the fetus have different chromosomes, which is one source of false positives and false negatives.

Can NIPT Be Done Before 10 Weeks?

Researchers have explored whether pushing NIPT earlier could give parents faster answers, especially in pregnancies conceived through IVF where the gestational age is known precisely. A study that performed NIPT between roughly 6 and 10 weeks found that results matched the standard 12-week NIPT in all but one case, which was a test failure rather than a wrong result.³ Another study confirmed that NIPT is highly reliable when blood is drawn between 8 and about 13 weeks.⁴

These findings are encouraging but come from small cohorts. The 6-to-9-week study included only 30 participants and had no cases of the major trisomies to detect, so it could only confirm that the test correctly identified normal chromosomes and fetal sex at that early stage. Until larger validation studies are published, 10 weeks remains the clinical standard. If you are eager to test as early as possible, most labs will draw blood right at 10 weeks by your dating ultrasound.

How Body Weight Shifts the Practical Window

Your weight is one of the biggest factors determining whether NIPT will work on the first draw. The fetal fraction tends to be lower in women with a higher BMI because more of their own DNA dilutes the placental signal. In women of normal weight, about 4.5% had a fetal fraction below the 4% threshold. In women with obesity, that rose to about one in five, and in women with severe obesity it climbed to roughly a third.⁵ When the lab cannot get enough fetal fraction, you get what is called a “no call” or indeterminate result, meaning the test cannot be interpreted.

Waiting a few more weeks can help because fetal fraction rises with gestational age, but the weekly increase is smaller the more you weigh. At 9 to 12 weeks, women under about 150 pounds had a no-call rate of just 0.14%, while women over 400 pounds had a rate of over 17%. Even by 13 to 18 weeks, about 6.5% of women in the heaviest weight category still received an uninterpretable result.⁶ In the highest weight range, fetal fraction crept up by only about half a percentage point per week.

This has practical implications for timing. One research group found that obesity raised the odds of an indeterminate result sixfold and that fetal fraction was consistently lower in obese women at every gestational week during the first trimester, without catching up over those weeks.⁷ Some clinicians now advise women with higher BMIs to consider delaying NIPT past 12 weeks or to plan for the possibility of a redraw rather than testing at the earliest window.

Medications That Can Interfere with Timing

Anticoagulant medications, particularly low-molecular-weight heparin (LMWH), are another practical consideration. Women on anticoagulants had significantly lower fetal fractions and more than an eightfold increase in the chance of getting an indeterminate result, even after adjusting for BMI and gestational age.⁸ Heparin interferes with the DNA amplification step in the lab process. In a separate report, 23 non-reportable results were traced to patients on LMWH, and most of those samples failed for insufficient fetal DNA rather than outright lab error.⁹ Even redrawing the blood often reproduced the same failure.

Aspirin alone appears less problematic. While fetal fraction was slightly lower in women taking aspirin, the rate of indeterminate results was not meaningfully different from women on no blood-thinning medication at all.⁸ If you are on heparin, your provider should know that NIPT may require special handling or that alternative screening may be worth discussing.

What Happens When the First Draw Fails

Getting a “no result” is understandably stressful, but it does not mean something is wrong with the pregnancy. About 0.8% of women fail the first test, and on a second draw roughly 80% of those get a usable result.¹⁰ However, the success rate of a redraw varies. For women of normal weight, reprocessing or redrawing was successful about 79% of the time, compared with about 56% for women with obesity.⁵

Timing the redraw matters. Since fetal fraction rises as pregnancy progresses, waiting a couple of weeks before a second blood draw is more effective than immediately redrawing. Some labs will reprocess the original sample first and only request a new blood draw if that also fails. Your provider can help decide whether a redraw or a shift to a different screening method makes more sense given your specific situation.

How Fetal Fraction Changes Throughout Pregnancy

The fetal fraction is not a fixed number. In a large study of over 150,000 pregnancies, the median fetal fraction at 12 to 16 weeks was about 11%. By 21 to 24 weeks it climbed to roughly 12%, and after 25 weeks it reached about 15%.¹¹ That steady rise means NIPT can technically be performed at any point from 10 weeks through the rest of pregnancy.

One quirk: the rise is not perfectly smooth. Some data suggest a temporary dip in fetal fraction around 15 weeks before the upward trend resumes.¹² This dip is subtle and unlikely to cause a test failure on its own, but it is worth knowing about if a borderline sample happens to be drawn right around that gestational age. Both increasing maternal age and higher BMI also tend to push fetal fraction down at any given week of pregnancy.

Twins, Vanishing Twins, and Other Complex Pregnancies

NIPT works in twin pregnancies, but the timing and interpretation are a bit different. Each placenta contributes its own fragment pool, and the fetal fraction is driven by whichever twin contributes less. For trisomy 21 screening in twins, pooled data show sensitivity around 99% and specificity near 100%, which is reassuring.¹³ A large commercial dataset of nearly 19,000 twin NIPT results found positive predictive values of about 89% for trisomy 21 and 73% for trisomy 18.¹⁴

Vanishing twin pregnancies, where one twin stops developing early on, create a trickier situation. The demised twin’s placental tissue can continue shedding DNA into your blood, potentially flagging a chromosomal problem that belongs to the lost twin rather than the surviving baby. In one large study, the positive predictive value for trisomy 21 in vanishing twin pregnancies was only about 41%, meaning most positive results were false positives driven by the demised twin’s DNA. Notably, none of the trisomy 18, trisomy 13, or other flagged findings in vanishing twin cases were confirmed in the surviving fetus.¹⁵ That same study found no false-positive results when NIPT was performed after 15 weeks in vanishing twin pregnancies, suggesting that waiting longer allows the demised twin’s DNA to clear. SNP-based NIPT platforms can sometimes detect the extra set of fetal DNA and flag the situation, which helps avoid incorrect sex calls and false positives.¹⁶

What NIPT Actually Screens For, and Where Its Accuracy Varies

Across large studies, NIPT detects trisomy 21 (Down syndrome) with sensitivity above 99% in both general-risk and high-risk populations, with a false-positive rate under 0.1%.¹⁷ Trisomy 18 and trisomy 13 are also detected with high sensitivity, though trisomy 13 has slightly more variability across studies. One large retrospective study reported sensitivity of about 99% for trisomy 21, 98% for trisomy 18, and 100% for trisomy 13, with positive predictive values of roughly 87%, 57%, and 18% respectively.¹⁸ That low predictive value for trisomy 13 means a positive flag is more often wrong than right for that particular condition, which is why confirmatory testing is always recommended.

Sex chromosome conditions are where NIPT becomes less reliable. Sensitivity for detecting monosomy X (Turner syndrome) ranges from about 84% to 94% depending on the lab method, and the positive predictive value is notably low. Large studies have reported positive predictive values for monosomy X as low as about 12% to 23%, meaning the vast majority of positive screens turn out to be false alarms.¹⁹ Other sex chromosome trisomies (like XXY or XXX) perform somewhat better, with predictive values in the 50% to 83% range.¹⁹

Extended Panels for Microdeletions and Rare Conditions

Some labs offer expanded NIPT panels, sometimes marketed as “NIPT-Plus,” that screen for microdeletion and microduplication syndromes (like DiGeorge syndrome) and rare autosomal trisomies beyond the standard 13, 18, and 21. These panels cast a wider net, but accuracy drops considerably for the additional conditions. In one study of expanded screening, the overall positive predictive value for all chromosomal abnormalities combined was 60%, meaning four in ten flagged cases were false positives.²⁰ The predictive value for microdeletions specifically was around 38%, and for rare trisomies about 25% to 50%.²¹

This does not mean these panels are useless, but it does mean positive results from an expanded panel are more likely to be wrong than positive results from standard NIPT. The timing window is the same as for standard NIPT, from 10 weeks onward, and the same fetal-fraction requirements apply. Whether you opt for an extended panel is a conversation worth having with a genetic counselor, especially since the anxiety of a false positive for a rare condition can be substantial.

What Follows a Positive NIPT Result

Because NIPT is a screening test, not a diagnostic one, a positive result needs to be confirmed through an invasive procedure: either chorionic villus sampling (CVS) or amniocentesis. CVS can be performed earlier, typically from about 10 to 13 weeks, while amniocentesis is generally done from around 15 to 16 weeks onward.²² That gap creates a practical tension: NIPT can flag something at 10 weeks, but if amniocentesis is the recommended follow-up, you may wait several more weeks before getting a definitive answer.

The choice between CVS and amniocentesis also depends on which chromosome is involved. For conditions with high rates of confined placental mosaicism, where the placenta has a chromosomal difference that the fetus does not share, trisomy 13 and monosomy X being common examples, amniocentesis gives a more definitive answer because it samples fetal cells directly. For trisomies involving chromosomes with imprinted genes, CVS may be recommended first with amniocentesis as a backup if the result is abnormal.²³

Incidental Findings and Maternal Health

Because NIPT reads DNA fragments from both you and the placenta, it occasionally picks up signals that have nothing to do with the baby’s chromosomes. Maternal copy-number variants, which are structural differences in the mother’s own DNA, can mimic a fetal trisomy signal. Researchers investigating discordant prenatal test results found that maternal duplications on chromosome 18 were the likely cause of false positive trisomy 18 flags in two cases.²⁴

More strikingly, NIPT has occasionally uncovered undiagnosed cancers in pregnant women. Tumors shed abnormal DNA into the bloodstream, and when NIPT detects chaotic signals across multiple chromosomes simultaneously, it can be a marker of maternal malignancy. In a study of nearly two million pregnancies, patterns of multiple chromosomal abnormalities on NIPT carried a positive predictive value of about 7.6% for diagnosing maternal cancer, and reproducible patterns pushed that to nearly 10%.²⁵ This is a rare outcome, but it is a real one, and it means that unusual multi-chromosome flags on NIPT may prompt your provider to investigate your health as well as the baby’s.

Sample Handling and Logistics

Once blood is drawn, the sample needs to reach the lab with the fetal DNA intact. Specialized blood collection tubes, like Streck tubes, stabilize cell-free DNA and prevent your white blood cells from breaking down and flooding the sample with maternal DNA. Studies have shown these tubes keep the fetal DNA fraction stable for up to seven days at room temperature, and across a wide range of temperatures from refrigerated to hot.²⁶ Newer tube brands perform comparably, with no significant difference in fetal fraction or library quality compared to the standard Streck tubes.²⁷

This matters if you live far from a processing lab or if your provider ships samples rather than processing them on-site. The seven-day stability window makes NIPT accessible even in rural or remote settings, as long as the right tubes are used. If your blood is drawn into standard EDTA tubes instead, the sample needs to be processed much more quickly or the maternal DNA contamination can overwhelm the fetal signal.

The Emotional Side of Early Testing

Having access to screening results early in pregnancy brings real psychological benefits alongside genuine anxieties. Research tracking women’s mental state before and after receiving NIPT results shows a consistent pattern: anxiety drops substantially once a low-risk result comes back. In one study, about 30% of women had elevated anxiety scores before testing, and that fell to about 14% after they received reassuring results. Decisional regret was very low, with essentially no women scoring above the midpoint on a standard regret scale. Women who started with high anxiety because of an elevated-risk result on traditional screening saw their anxiety drop to the same level as lower-risk women once NIPT came back normal.²⁸

The flip side is that early testing means confronting difficult information earlier, when there may be fewer people who even know about the pregnancy. Women who received insufficient pre-test counseling about what NIPT can and cannot tell them were more likely to experience regret about their decision to test. That finding argues for having a conversation with a genetic counselor or well-informed provider before the blood draw, rather than treating it as just another routine lab order. Understanding ahead of time that a positive NIPT is not a diagnosis, and that many positives (especially for rarer conditions) turn out to be false alarms, can make a real difference in how you process the results.